No Data
No Data
How long can the American customer love myth of high growth last? | Insight Research
Despite 3 consecutive years of high performance growth, market concerns about Aimeike's future growth momentum have not been resolved.
Is the healthcare market recovering? Mindray Healthcare acquires control of Whitney Healthcare at 25% premium | Insight Research
In the new year, A was born, and the leading device company Mindray entered the cardiovascular field at a premium.
Behind the slowdown in Aimeike's growth rate in the 3rd quarter: “Women's Maotai” can't handle the slump in consumption?
Demand weakens
Medical beauty earns 200 million dollars a month and has to participate in the internal volume of diet pills. Where is the boundary of America's ambition?
It's not easy to take diet pills
Nvidia is leaving AI pharmaceuticals, are CXO companies expected to take off?
Performance implementation pending examination
Read Huitai Medical 2021 China News
According to the Securities Star data Center, Huitai Medical 2021 reported that the company's main income was 385 million yuan, up 99.44% from the same period last year; the net profit from its parent was 115 million yuan, up 186.24% from the same period last year; deducting 101 million yuan from non-net profit, up 177.39% from the same period last year; debt ratio 11.57%, investment income 16.1209 million yuan, financial expenses-207200 yuan, gross profit margin 70.11%. There are three new shareholders in this period. China China Construction Bank Corporation Co., Ltd.-SSIC JPMorgan Health Stock Securities Investment Fund holds 315819 shares, accounting for circulation.